Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%

MT Newswires Live

Jan 29, 2025

Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.

The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.

The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.

A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.

The firm's shares rose past 7% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507215508"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507215508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507215508?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507215508","market":"nz","top_or_hot":-1,"title":"Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenerve Says Sales Jump 260% in December 2024 Quarter; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-29 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.</p><p>The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.</p><p>The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.</p><p>A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.</p><p>The firm's shares rose past 7% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNV.AU","symbol_name":"Renerve Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507215508","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507215508","pubTimestamp":1738125248,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Renerve  said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RNV.AU":"Renerve Ltd"},"translate_title":"Renerve表示2024年12月季度销售额增长260%；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNV.AU":0.9},"content_text":"Renerve (ASX:RNV) said its sales for the fiscal quarter ended Dec. 31, 2024, came in at AU$52,000, representing a 260% increase from a year earlier, according to a Wednesday Australian bourse filing.The company reached an exclusive distribution agreement with Accession Medical Supplies for the sales and marketing of NervAlign Nerve Cuff in Hong Kong and Macau in December 2024, the filing said. It also entered an exclusive distribution agreement with Union MediScience in the Middle East, covering Bahrain, Saudi Arabia, Kuwait, UAE, and Qatar.The company said it continues to focus on expanding sales of NervAlign Nerve Cuff in its core US market.A clinical study investigating NervAlign on neurectomies repair is ongoing, with data expected to be released late in the third quarter of fiscal 2025, per the filing.The firm's shares rose past 7% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}